Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tecan Group (TECN) Fair Value & Analysis

Healthcare · CH · Market cap CHF 2.0B

PriceCHF 150.00
Fair ValueCHF 108.57
Upside-27.6%
Quality95/100
Evidence: High Range CHF 76.32 – CHF 139.34

Analysis

Tecan Group (TECN) currently trades at CHF 150.00, while our model-based Fair Value estimate is CHF 108.57 — implying the stock looks roughly 27.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -55% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -43% Medline Inc (MDLN) -13% Becton, Dickinson and Company (BDX) -28% Alcon Inc (ALC) -33%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.